Autolus Therapeutics PLC (AUTL) Stock AnalysisAUTLAutolus Therapeutics PLC

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Autolus Therapeutics PLC is currently trading at $1.54, significantly below the analyst price target of $10, indicating potential upside. However, the stock has an RSI of 28.82, suggesting it is oversold, but it has also experienced a 16.98% decline over the past 20 days, indicating a bearish trend. The company reported a gross margin of 57.61% in Q2 2026, a substantial improvement from previous quarters, which reflects operational efficiencies. The main risk is the negative net income reported at -$39.11 million in Q2 2026, which could affect investor confidence. Therefore, while there is potential for growth, caution is advised due to recent performance trends and ongoing losses.

2 analysts cover AUTL: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.18.